一项针对B型血友病的Etranacogene Dezaparvovec研究的最终分析
Steven W Pipe1, Wolfgang Miesbach2, Michael Recht3,4
1Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor.
The New England journal of medicine
|December 8, 2025
概括
基因疗法与埃特拉纳科根 dezaparvovec提供单剂量治疗血友病B,显著降低出血率和因子IX消耗超过五年.
科学领域:
- 基因治疗 基因治疗
- 血液学 血液学 血液学
- 临床试验 临床试验
背景情况:
- 传统上,B型血友病的治疗需要终身注射因子IX.
- 基因疗法具有单剂量治疗的潜力,具有持久的因子IX表达.
- 埃特拉纳科根使用AAV5载体和帕多瓦因子IX变体.
研究的目的:
- 评价乙甲基 dezaparvovec 在血友病 B 患者的长期疗效和安全性.
- 在5年的随访期内评估持续的因子IX表达和出血率.
主要方法:
- 这是一项开放式的第三阶段研究,涉及单次输注乙甲基 dezaparvovec.
- 参与者患有B型血友病,因子IX活性≤2 IU/dL.
- 5年分析包括调整后的年均出血率,XIX因子表达和安全结果.
主要成果:
- 调整后的年均出血率有63%的降低 (1.52比4.16).
- 维持了稳定的内源性因子IX表达,在5年内平均活性为36.1 IU/dL.
- 在5年期间,外源性XI因子消耗量下降了96%.
结论:
- 在5年内,Etranacogene dezaparvovec表现出持续的因子IX表达和降低的出血率.
- 基因疗法与IX因子消耗的显著下降有关.
- 在输液后6个月后,可能与治疗相关的不良事件很少发生.
更多相关视频
10:42Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
Published on: April 11, 2019
10.4K
18:30RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells
Published on: February 13, 2013
22.4K
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis III: Interprofessional Care
265
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
265
